Ambeed.cn

首页 / 抑制剂/激动剂 / 内分泌学/激素 / ERR / (R)-Equol

(R)-雌马酚 /(R)-Equol {[allProObj[0].p_purity_real_show]}

货号:A620368 同义名: R-雌马酚 / Isoequol;(+)-Equol

(R)-Equol is an agonist of both ERα and ERβ with Kis of 27.4 and 15.4 nM, respectively.

(R)-Equol 化学结构 CAS号:221054-79-1
(R)-Equol 化学结构
CAS号:221054-79-1
(R)-Equol 3D分子结构
CAS号:221054-79-1
(R)-Equol 化学结构 CAS号:221054-79-1
(R)-Equol 3D分子结构 CAS号:221054-79-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

(R)-Equol 纯度/质量文件 产品仅供科研

货号:A620368 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >

(R)-Equol 生物活性

描述 (R)-Equol is an agonist of ERα and ERβ with Ki of 27.4 nM and 15.4 nM, respectively[1].(R)-Equol dose-dependently inhibited the invasive capacity of MDA-MB-231 cells, with a significant effect at the highest concentration tested (50 μM). After 48 h of exposure to (R)-Equol, 50 μM (R)-Equol reduced the invasive capacity by 62%. The expression of MMP-2 was significantly down-regulated after treatment with 50 μM (R)-Equol[2].

(R)-Equol 动物研究

Animal study Animals fed (R)-Equol showed a significant reduction in the number of palpable tumors over time compared to controls. In addition, the number of palpable tumors formed per rat was also significantly lower in the (R)-Equol-fed group than in the rats treated with S-(-)equol. The number of tumours in the (R)-Equol fed animals was 43% less than in the control group. The number of tumours/number of tumoured animals was significantly lower in (R)-Equol-fed animals compared to controls (3.3 ± 0.4 versus 5.5 ± 0.5). At autopsy, the mean tumour weight per animal was significantly lower in rats fed (R)-Equol compared to controls. Feeding (R)-Equol resulted in a significant prolongation of tumour latency[3].

(R)-Equol 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01116310 Postmenopausal Women With Mode... 展开 >>rate Vasomotor Symptoms 收起 << Phase 4 Unknown July 2012 Spain ... 展开 >> Hospital Central de Asturias Withdrawn Asturias, Spain, H. Central de Asturias Hospital del Cruces Recruiting Barakaldo, Spain, 48903 Principal Investigator: José L. Neyro, Dr.          Assir CAP Sant Martí Withdrawn Barcelona, Spain, 08020 Hospital de la Santa Creu i Sant Pau Recruiting Barcelona, Spain, 08025 Principal Investigator: Misericordia Guinot, Dr.          USP Instituto Universitario Dexeus Active, not recruiting Barcelona, Spain, 08028 ASSIR CAP San Andreu Active, not recruiting Barcelona, Spain, 08030 Hospital Universitari Vall d'Hebrón Recruiting Barcelona, Spain, 08035 Principal Investigator: Francesc Baró, Dr.          Hospital Monteprincipe Recruiting Boadilla del Monte, Madrid, Spain, 28660 Principal Investigator: Manuel Marcos, Dr.          Hospital General de Ciudad Real Active, not recruiting Ciudad Real, Spain, 13005 Centro Diatros Recruiting Gavá (Barcelona), Spain, 08850 Principal Investigator: Rafael Sánchez Borrego, Dr.          Hospital Universitario de Guadalajara Recruiting Guadalajara, Spain, 19002 Principal Investigator: María J. Cancelo, Dr.          Consorci Sanitari d l´Anoia-H. de Igualada Recruiting Igualada, Barcelona, Spain, 08700 Principal Investigator: Ana R Pérez Aguado, Dr.          Centro de Estudios de Obstetricia y Ginecología Asociado Lugo Recruiting Lugo, Spain, 27002 Principal Investigator: Francisco Vázquez, Dr.          Gabinete Médico Velázquez Recruiting Madrid, Spain, 28001 Principal Investigator: Silvia González, Dr.          Instituto Palacios Recruiting Madrid, Spain, 28009 Principal Investigator: Santiago Palacios, Dr.          Hospital Mateu Orfila Withdrawn Mao, Spain, 07701 H. San Joan d'Alacant Recruiting San Juan, Alicante, Spain, 03550 Principal Investigator: Francisco Quereda, Dr.          Hospital Universitario La Fe Recruiting Valencia, Spain, 46009 Principal Investigator: Dolores Juliá, Dr.          Hospital Doctor Pesset Recruiting Valencia, Spain, 46017 Principal Investigator: Antonio Cano, Dr.          Hospital Miguel Servet Withdrawn Zaragoza, Spain, 50009 收起 <<

(R)-Equol 参考文献

[1]Setchell KD, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9.

[2]Magee PJ, et al. Daidzein, R-(+)equol and S-(-)equol inhibit the invasion of MDA-MB-231 breast cancer cells potentially via the down-regulation of matrix metalloproteinase-2. Eur J Nutr. 2014 Feb;53(1):345-50.

[3]Brown NM, et al. The chemopreventive action of equol enantiomers in a chemically induced animal model of breast cancer. Carcinogenesis. 2010 May;31(5):886-93.

(R)-Equol 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.13mL

0.83mL

0.41mL

20.64mL

4.13mL

2.06mL

41.28mL

8.26mL

4.13mL

(R)-Equol 技术信息

CAS号221054-79-1
分子式C15H14O3
分子量 242.27
别名 R-雌马酚 ;Isoequol;(+)-Equol
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,Store in freezer, under -20°C

溶解度

DMSO: 105 mg/mL(433.4 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。